At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PHAT Phathom Pharmaceuticals
Trading 12-11 15:06:24 EST
14.67
+0.12
+0.79%
High14.79Low14.46Vol221.82K
Open14.62D1 Closing14.55Amplitude2.30%
Mkt Cap1.04BTradable Cap761.85MTotal Shares71.14M
T/O3.24MT/O Rate0.43%Tradable Shares51.95M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Barclays Initiates Phathom Pharmaceuticals at Equalweight With $16 Price Target
MT Newswires Live  ·  12-09 20:54
Barclays Initiates Phathom Pharmaceuticals at Equalweight With $16 Price Target
Indonesia Probes 12 Legal Entities Over Forest Destruction Behind Sumatra Floods
Tempo  ·  12-06
Indonesia Probes 12 Legal Entities Over Forest Destruction Behind Sumatra Floods
Phathom Pharmaceuticals (PHAT): Assessing Valuation After First Patient Dosed in VOQUEZNA EoE Phase 2 Trial
Simply Wall St.  ·  11-13
Phathom Pharmaceuticals (PHAT): Assessing Valuation After First Patient Dosed in VOQUEZNA EoE Phase 2 Trial
Phathom Pharmaceuticals Inc - Topline Results Expected in 2027
THOMSON REUTERS  ·  11-04
Phathom Pharmaceuticals Inc - Topline Results Expected in 2027
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Voquezna® (Vonoprazan) in Eosinophilic Esophagitis (Eoe)
THOMSON REUTERS  ·  11-04
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Voquezna® (Vonoprazan) in Eosinophilic Esophagitis (Eoe)
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
GlobeNewswire  ·  11-04
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
Phathom Pharmaceuticals Inc - Topline Results of Phase 2 Eoe Study Expected in 2027
THOMSON REUTERS  ·  11-04
Phathom Pharmaceuticals Inc - Topline Results of Phase 2 Eoe Study Expected in 2027
Phathom Pharmaceuticals to Present at Jefferies Global Healthcare Conference
Reuters  ·  11-03
Phathom Pharmaceuticals to Present at Jefferies Global Healthcare Conference
Phathom Pharmaceuticals’ Q3 Earnings: Strong Growth Amid Challenges
TIPRANKS  ·  11-01
Phathom Pharmaceuticals’ Q3 Earnings: Strong Growth Amid Challenges
Stock Track | Phathom Pharmaceuticals Soars 8.41% on Strong Q3 Results and Analyst Upgrade
Stock Track  ·  10-31
Stock Track | Phathom Pharmaceuticals Soars 8.41% on Strong Q3 Results and Analyst Upgrade
Stock Track | Phathom Pharmaceuticals Soars 8.41% on Strong Q3 Results and Analyst Upgrade
Stock Track  ·  10-31
Stock Track | Phathom Pharmaceuticals Soars 8.41% on Strong Q3 Results and Analyst Upgrade
Stock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Results and Analyst Upgrade
Stock Track  ·  10-31
Stock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Results and Analyst Upgrade
Stock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Earnings and Analyst Upgrade
Stock Track  ·  10-31
Stock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Earnings and Analyst Upgrade
Phathom Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  10-31
Phathom Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Phathom Pharmaceuticals: Strong Q3 Performance and Promising Growth Drive Buy Rating
TIPRANKS  ·  10-31
Phathom Pharmaceuticals: Strong Q3 Performance and Promising Growth Drive Buy Rating
Stock Track | Phathom Pharmaceuticals Soars 10.50% Pre-Market on Strong Q3 Results and Raised Guidance
Stock Track  ·  10-30
Stock Track | Phathom Pharmaceuticals Soars 10.50% Pre-Market on Strong Q3 Results and Raised Guidance
Stock Track | Phathom Pharmaceuticals Soars 10.50% on Strong Q3 Results and Raised 2025 Guidance
Stock Track  ·  10-30
Stock Track | Phathom Pharmaceuticals Soars 10.50% on Strong Q3 Results and Raised 2025 Guidance
Craig-Hallum Sticks to Its Buy Rating for Phathom Pharmaceuticals (PHAT)
TIPRANKS  ·  10-30
Craig-Hallum Sticks to Its Buy Rating for Phathom Pharmaceuticals (PHAT)
Stock Track | Phathom Pharmaceuticals Soars 6.43% Pre-market on Strong Q3 Results and Raised Guidance
Stock Track  ·  10-30
Stock Track | Phathom Pharmaceuticals Soars 6.43% Pre-market on Strong Q3 Results and Raised Guidance
Phathom Q3 revenue up 25%, beats estimates
Reuters  ·  10-30
Phathom Q3 revenue up 25%, beats estimates

Introduction

Company Name.
Phathom Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Issue price:
--